Written by Ashley L. Morgan
Published on Vol 5 Issue 2, 2025
Targeted inhibition of the HER2 pathway has dramatically enhanced survival rates among patients diagnosed with metastatic hormone receptor-negative, HER2-positive (HR−/HER2+) breast carcinoma. Nonetheless, the underlying influences guiding its clinical use are still not fully understood. This investigation explores clinical, demographic, and institutional predictors influencing the administration of HER2-focused treatments in individuals with metastatic HR−/HER2+ disease. Using the National Canc
Written by S. Benali
Published on Vol 5 Issue 2, 2025
Administering testosterone at levels exceeding the physiological range, especially when alternated with anti-androgen therapy in men with metastatic castration-resistant prostate cancer (CRPC), has yielded notable benefits in clinical trials. As this approach becomes increasingly implemented in practice, it is essential to clarify how resistance develops. For this purpose, three distinct CRPC cell models responsive to testosterone were independently generated. From each model, lines resistant to
Written by C. Georgiou
Published on Vol 5 Issue 2, 2025
The use of prehabilitation has grown among individuals undergoing multimodal management for oesophagogastric cancer (OGC). Most available research has consisted of limited, single-centre studies. This multi-institutional project was designed to evaluate how prehabilitation influences outcomes after surgery for OGC. Information was pooled from four prospective studies conducted in the UK and Ireland involving patients treated with multimodality therapy for OGC. These included three randomised tri
Written by O. Shevchenko
Published on Vol 5 Issue 2, 2025
This research sought to determine if individuals diagnosed with prostate cancer (PCa) would transition to castration-resistant prostate cancer (CRPC) within 12 months following hormone-based therapy. Ninety-six men with PCa who had complete baseline clinical information and underwent multiparametric magnetic resonance imaging (MRI) between September 2018 and September 2022 were retrospectively analyzed. Participants were categorized according to whether they progressed to CRPC after 12 months of
Written by J. Wilson
Published on Vol 5 Issue 2, 2025
Clinical research is meant to serve all communities. For this reason, the National Cancer Institute expects each cancer center to recruit participants in numbers that reflect the cancer prevalence in their service regions. However, many centers do not achieve this balance. The individual who obtains consent for participation often interacts most closely with potential subjects. We proposed that the ethnic, racial, and linguistic background of the consenter could meaningfully influence a person’s
Written by Ashley L. Morgan
Published on Vol 5 Issue 2, 2025
Large, consistently treated breast cancer (BC) cohorts with extended monitoring remain uncommon for evaluating long-term outcomes. The Institut Català d’Oncologia (ICO) Breast Cancer Cohort was established to describe real-world treatment tendencies and 5- and 10-year overall survival, emphasizing patients younger than 40 and those aged 70 or above—groups often lacking representation in trials. This retrospective observational analysis included all individuals with histologically verified invasi
Written by Alexey Morozov
Published on Vol 5 Issue 2, 2025
Biochemical recurrence (BCR) is observed in about 20-50% of individuals with localized prostate cancer (PC) after undergoing radical prostatectomy (RP). Standard imaging methods generally fail to identify early relapse, either local or systemic, when PSA concentrations are low. The use of 18F-DCFPyL PSMA positron emission tomography/computed tomography (PET/CT) provides improved diagnostic precision and detection sensitivity in recurrent cases. This research investigates how effectively 18F-DCFP
Written by M.A. Reyes
Published on Vol 5 Issue 2, 2025
Sacituzumab govitecan (SG), an antibody-drug conjugate directed at Trop-2, has been approved for metastatic triple-negative breast cancer (mTNBC) and more recently for hormone receptor-positive/HER2-negative metastatic breast cancer (mHRPBC). Although its efficacy has been proven in controlled clinical trials, real-world insights—particularly those including both molecular subtypes—are still limited. This multicenter, retrospective investigation assessed real-world clinical effectiveness, tolera
Written by Jin-Ho Park
Published on Vol 5 Issue 2, 2025
Compared with the general population, individuals with gastric cancer (GC) experience higher rates of atrial fibrillation (AF) and cardiovascular death. Yet, the influence of cancer stage on AF development has not been well defined. This research assessed how GC stage, classified by the Surveillance, Epidemiology, and End Results (SEER) system, relates to AF risk. A retrospective cohort analysis was conducted using anonymized data from South Korea’s Cancer Public Library Database, including pati
Written by Christopher S. Allen
Published on Vol 5 Issue 2, 2025
Abstract Multiparametric MRI (mpMRI) is a key, non-invasive imaging approach used to identify and localize prostate cancer (PCa). When integrated with radiomic feature extraction, mpMRI data can assist in estimating tumor aggressiveness. Although T2 mapping delivers quantitative metrics useful for PCa assessment, it is not yet routinely implemented in clinical imaging workflows. Our team previously introduced a deep learning framework capable of generating estimated T2 maps from standard T1- and
Written by V.H. Nguyen
Published on Vol 5 Issue 2, 2025
Many breast cancer survivors (BCS) continue to face lasting side effects, among which breast cancer–related lymphedema (BCRL) is especially frequent. Exercise is generally recognized as a safe approach to support recovery and enhance daily functioning in BCS, either living with or susceptible to BCRL. Yet, the influence of combined aerobic and resistance (concurrent) training in this group is not well established. This investigation assessed the impact of a 12-week guided concurrent exercise reg
Written by M Rojas
Published on Vol 5 Issue 2, 2025
The combination therapy of Durvalumab and Tremelimumab (Dur/Tre) has shown promise in treating advanced hepatocellular carcinoma (HCC). Nonetheless, reliable factors that predict therapeutic benefit and survival outcomes remain largely undefined. This study retrospectively assessed variables influencing clinical outcomes and treatment response in HCC patients receiving Dur/Tre. A total of 30 patients were retrospectively analyzed in this single-institution study to identify indicators of Dur/Tre
Established in 2019, Galaxy Publication stands as a global academic publishing house focused on advancing scholarly work across medicine, nursing, and health sciences. Through its network of peer-reviewed journals, the organization brings together original research and academic contributions from scholars around the world, creating a shared space for knowledge exchange and intellectual collaboration.
